tbuckley/cabot-search huggingface dataset:
Abstract 1095: Comprehensive miRNA profiling of taxane-resistant human breast and ovarian cancer cell lines using the SmartChip real-time PCR system
Authors: George E. Duran, Cindy Y. Wang, E. Brian Francisco, Kee Wong, Nicole Robinson, Branimir I. Sikic
Journal: Cancer Research (2012)

Abstract MiRNAs are post-transcriptional regulators of cell proliferation, tissue differentiation, embryonic development and apoptosis. We profiled the expression of miRNAs in a panel of taxane-resistant human breast and ovarian cancer cell lines using the recently developed WaferGen SmartChip System. Four breast cancer cell lines (MCF-7, BT-549, MDA-MB-231 and T-47D) and four ovarian cancer cell lines (1A9/A2780, ES-2, MES-OV and OVCAR-3) were selected for resistance to either docetaxel or paclitaxel alone or co-selected with taxane in the presence of the P-glycoprotein inhibitor, PSC-833 (valspodar, 2 µM). All of the variants established by exposure to taxanes alone are MDR1/ABCB1(+), whereas the resistance observed in the co-selected variants is not transporter-mediated. We have previously reported elevated class III β-tubulin (TUBB3) content, reduced BRCA1 and elevated CDKN1A (p21) in the majority of the non-MDR1 taxane variants relative to parental controls. For miRNA profiling, total RNA was analyzed using the SmartChip Human MicroRNA Panel version 2.0 containing 1,150 unique real-time PCR reactions in quadruplicate for a total of ∼4,600 reactions per sample. Following ligation to a miRNA cloning linker (Integrated DNA Technology, Coraville, IA), the equivalent of 500 ng of starting RNA per sample was added to a one-step cDNA and real-time PCR cocktail (Applied Biosystems, Foster City, CA). The total volume per reaction was 100 nL containing an equivalent of 96 pg of RNA. Forty cycles of real-time PCR were performed on the SmartChip Cycler and a quality screen was performed to remove any outlier data. MiRNA profiling is complete and an analysis of these data revealed a clear separation between the two sets of non-MDR1 variants based on tumor type (breast vs. ovarian), and selection conditions (non-MDR1 vs. parental). We observed reduced miR-200 family expression in the majority of these taxane-resistant variants, consistent with published findings that miR-200c directly targets and suppresses TUBB3. Furthermore, Significance Analysis of Microarrays (SAM) software identified reduced miR-635, miR-296-3P, and let-7B in both MDR1(+) and MDR1(-) variants of breast origin, and elevated let-7 family (let-7B, let-7F and let-7I) and reduced miR-1225-5P and miR-4286 in the ovarian cell lines relative to parental controls. The functional significance of these observations will be studied by introducing miRNA inhibitors or mimics specific to key alterations with the goal of sensitizing cells to taxanes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1095. doi:1538-7445.AM2012-1095
Delayed introduction of G‐CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high‐risk malignancies: Retrospective study of 45 cases
Authors: Igor Dolgopolov, Ludmila Andreeva, Maxim Yankelevich, Demur Mscheidze, Stuart Siegel, George Mentkevich
Journal: American Journal of Hematology (2003)

Abstract We retrospectively compared the effects of two time points of G‐CSF (Filgrastim) introduction for PBSC mobilization in 45 children with different malignancies. Seventeen patients received the first G‐CSF dose on day 2 or 3 following chemotherapy (group 1). Twenty‐eight patients received a “flexible” G‐CSF injection schedule when the G‐GSF was started at the time of the first platelet count rise during post‐chemotherapy recovery phase (group 2). Leukapheresis was performed when WBC recovery reached &gt;2.0 × 10 9 /l or if the peripheral blood CD34 + cell level was &gt;0.01 × 10 9 /l. A median of 2 (1–4) leukapheresis procedures was performed in both groups to yield a median of 4.2 and 6.1 × 10 6 CD34 + cells/kg in groups 1 and 2, respectively, which was generally sufficient for auto‐transplantation. The proportion of patients with a failure of PBSC collection was similar and G‐CSF consumption estimated through the total cycle dose was 2.3 times less in group 2 without increasing infectious risks. The short‐term hematological recovery and the early post‐transplant course were similar in the two groups. Delayed introduction of G‐CSF after chemotherapy allowed PBSC harvest equivalent to that obtained after early G‐CSF introduction. This approach could be an interesting alternative in PBSC mobilization but should be assessed by a prospective controlled study. Am. J. Hematol. 73:225–229, 2003. © 2003 Wiley‐Liss, Inc.
Natural History and Risk Factors for Microalbuminuria in Adolescents With Type 1 Diabetes
Authors: Monique L. Stone, Maria E. Craig, Albert K. Chan, Jenny W. Lee, Charles F. Verge, Kim C. Donaghue
Journal: Diabetes Care (2006)

To describe the natural history and risk factors for persistent microalbuminuria in children and adolescents with type 1 diabetes followed for up to 15 years.This study contained a longitudinal cohort of 972 patients; analysis of baseline risk factors was performed using logistic regression and predictors over time using survival analysis. Albumin excretion rate was measured on three consecutive timed overnight urine collections on at least two occasions. Normoalbuminuria was defined as a median albumin excretion rate < 7.5 microg/min, borderline microalbuminuria as 7.5-20 microg/min, and microalbuminuria as 20-200 microg/min. Microalbuminuria was further classified as persistent if its duration was >12 months. Median age was 12.7 years (interquartile range 11.5-14.4) and diabetes duration 6.5 years (4.1-9.3) at first assessment, and median follow-up was 6.2 years (range 1-15.3).The incidence of persistent microalbuminuria was 4.6 (95% CI 3.3-6.1) per 1,000 patient-years. Predictors of persistent microalbuminuria from the first assessment using multiple logistic regression were high cholesterol (odds ratio 2.2 [95% CI 1.2-4.0]) and borderline microalbuminuria (2.5 [1.2-5.2]). Predictors using Cox regression were HbA(1c) (hazard ratio 1.4 [95% CI 1.1-1.7]), age at diagnosis (1.2 [1.1-1.3]), obesity (3.6 [0.8-15.5]), and insulin dose (2.7 [1.0-7.5]).Children and adolescents with type 1 diabetes who have borderline microalbuminuria are more than twice as likely to develop persistent microalbuminuria. In addition to poor glycemic control, clinical markers of insulin resistance were associated with an increased risk of microalbuminuria.
Proteomics of Transformed Lymphocytes from a Family with Familial Pulmonary Arterial Hypertension
Authors: Barbara O. Meyrick, David B. Friedman, D. Dean Billheimer, Joy D. Cogan, Melissa A. Prince, John A. Phillips, James E. Loyd
Journal: American Journal of Respiratory and Critical Care Medicine (2007)

Not all family members with BMPR2 mutations develop pulmonary arterial hypertension (PAH), implying that additional modifier genes or proteins are necessary for full expression of the disease.To determine whether protein expression is altered in patients with familial PAH (FPAH) compared with obligate carriers and nondiseased control subjects.Protein extracts from transformed blood lymphocytes from four patients with FPAH, three obligate carriers, and three married-in control subjects from one family with a known BMPR2 mutation (exon 3 T354G) were labeled with either Cy3 or Cy5. Cy3/5 pairs were separated by standard two-dimensional differential gel electrophoresis using a Cy2-labeled internal standard of all patient samples. Log volume ratios were analyzed using a linear mixed-effects model. Proteins were identified by matrix-assisted laser desorption ionization, time-of-flight mass spectrometry (MALDI-TOF MS) and tandem TOF/TOF MS/MS.Hierarchical clustering, heat-map, and principal components analysis revealed marked changes in protein expression in patients with FPAH when compared with obligate carriers. Significant changes were apparent in expression of 16 proteins (P < 0.05) when affected patients were compared with obligates: nine showed a significant increase and seven showed a significant reduction.A series of novel proteins with altered expression were found that could distinguish affected patients from obligate carriers and married-in controls in a single family with a BMPR2 mutation. These differences provide new information highlighting proteins that may be involved in the mechanism(s) that differentiates those individuals with a BMPR2 mutation who develop FPAH from those who do not.
A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis
Authors: R.S. Flanc, F.Y. Ma, G.H. Tesch, Y. Han, R.C. Atkins, B.L. Bennett, G.C. Friedman, J.-H. Fan, D.J. Nikolic-Paterson
Journal: Kidney International (2007)
Diazoxide no longer marketed
Authors: J R Hall
Journal: BMJ (1992)

fragments on breaking in the manner described, glasses annually attests to the limited life of most covered that the manufacturers had made a Certainly the base, the thickest part, does fragment pub glasses.commercial decision to stop marketing diazoxide when a glass breaks, but this is not so with the thin Tempering will never completely eliminate tablets.When we asked how such a decision could si'de wall, which either remains intact or breaks inj'uries due to glass, but it substantially reduces be made without consultation we were informed into pieces with "razor blade" edges.the risk of breakage.As De Grave states in the that consultation, with endocrinologists had taken Interestingly, the French claim only that their conclusion of a paper cited by Grimes, "In fact, place.We have not yet been able to locate those glass is three times stronger than a normal, stress toughening has provided an opportunity for the consulted.free glass; we dispute this figure, let alone Shepherd production of high resistance tumblers, dishes,We invite other would be users of the drug and colleagues' claim that it is six times stronger.plates, bowls, casseroles, etc, of great variety of to write to the suppliers, Allen and Hanburys Breaking a used tempered glass does not present a shapes, and colours which are now normally used Limited, Stockley Park West, Uxbridge, Middle- problem to an assailant, and the same jagged by everyone."' sex UB 11 IBT, requesting that the drug once more shards characteristic of normal glassware on J P SHEPHERD be supplied as tablets.breakage are produced.
Concepts of Neurotic and Personality Disorders in ICD-10: Results of the Research Criteria Study
Authors: Aribert Muhs, Christina Öri
Journal: Psychotherapy and Psychosomatics (1995)

A discussion on personality disorders (F6) is conducted within the framework of the Research Criteria Study on the basis of one case each of borderline syndrome (F60.31), transsexualism (F64.0), and factitious disorder (F68.1). In the Research Criteria Study the main agreement achieved about personality disorders was 77%, for borderline disorders 94%, transsexualism 91%, and factitious disorders 53%. Additional diagnoses were given in the case of factitious disorder by 43%, for borderline disorders in 15%, and for transsexualism in only 3%. Alternative diagnoses improved the overall agreement about factitious disorders by 21%, about borderline disorders and about transsexualism by 3%. It appears justified to introduce a coding for an alternative main diagnosis. The diagnostic concepts are discussed with respect to practicality, suitability, adequacy and reliability. The raters felt fairly secure about the classification. The research diagnostic criteria proved to be very practical. The raters attributed a high reliability to ICD-10 and, with the exception of factitious disorders, a very valid image of patients.
[172] DETECTION OF HCV ANTIGENS IN EARLY POST-LIVER TRANSPLANT GRAFT BIOPSIES PREDICTS RECURRENT HEPATITIS C AFTER 1 YEAR IN PATIENTS TRANSPLANTED FOR HCV RELATED LIVER DISEASE
Authors: A. Grassi, C. Ouarneti, M. Susca, M. Ravaioli, V. Cipriano, A. D'Errico, C. Morelli, F. Piscaglia, M. Tame, P. Andreone, G.L. Grazi, D. Zauli, A.D. Pinna, F.B. Bianchi, G. Ballardini
Journal: Journal of Hepatology (2007)
749 A novel primeboost therapeutic vaccine induces sustained seroconversion at 52 weeks in patients with HBeAg+ chronic hepatitis B: A phase IIA clinical trial
Authors: J. Schneider, W. Halota, D. Delic, Z. Nesic, D. Prokopowicz, R. Flisiak, J. Kuydowicz, M. Jankowski, J. Cianciara, T. Mach, R. Modrzewska, M. Fabri, D. Tomic, A. Horban, W. Krvcka, M. Cripps
Journal: Journal of Hepatology (2006)
Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial
Authors: Andrés J. M. Ferreri, Silvia Govi, Markus Raderer, Antonino Mulè, Alessandro Andriani, Daniele Caracciolo, Liliana Devizzi, Fiorella Ilariucci, Stefano Luminari, Edi Viale, Leonhard Müllauer, Stefania Dell'Oro, Paolo Giorgio Arcidiacono, Maurilio Ponzoni, Caterina Patti
Journal: Blood (2012)
Toxicity Following Methoxyflurane Anesthesia
Authors: Donald R. Taves
Journal: JAMA (1970)

The concentrations of inorganic fluoride and nonvolatile organic fluoride were measured in a patient with nephrotoxic effects following methoxyflurane anesthesia. Concentrations of both were markedly elevated compared to two patients who received methoxyflurane without subsequent nephrotoxic effects. Indirect evidence suggests that the inorganic fluoride concentration was sufficient to account for the nephrotoxic effects. The prolonged elevation of inorganic fluoride observed can be explained on the basis of the breakdown of the nonvolatile organic fluoride to inorganic fluoride and the poor renal clearance of both types.
An Address on the Relation of Puerperal Fever to the Infective Diseases and Pyaemia
Authors: F. Barker
Journal: BMJ (1875)

I FEEL that I have no right to waste any of your time in personal topics, except briefly to express my grateful appreciation of the honour that I have received at your hands, and to appeal to your courtesy to excuse such deficiencies as may be charitably ascribed to weakness of the vocal organs, or to that embarrassment which a stranger must feel in addressing such a body of
Current Issues in Cancer Palliative care
Authors: C L Davis, J R Hardy
Journal: BMJ (1994)

Though many of the treatment strategies used in palliative care have never been subjected to clinical trial, it has been argued that advances in palliative care have outstripped those in many other specialties. This article is not a comprehensive review of therapeutic options, nor even of recent advances in this topic, but concentrates on the latest developments and controversies in the pharmacological treatment of four frequent and important symptoms: neuropathic pain, anorexia and cachexia, intestinal obstruction, and breathlessness. It is difficult to perform blinded, randomised trials in patients with advanced disease and poor performance status, yet it is these patients who may gain most from the adoption of new well evaluated treatment strategies.
The Polyglandular Failure Syndrome: Disease Inheritance, HLA Type, and Immune Function
Authors: GEORGE S. EISENBARTH
Journal: Annals of Internal Medicine (1979)

The occurrence of disease and the inheritance of histocompatibility leukocyte antigens (HLA) were evaluated in 11 patients with the polyglandular failure syndrome and 42 of their relatives. The gene frequency of the HLA-B8 allele (seven of 22) and the HLA-A1, B8 haplotype phenotype frequency (five of 11) were increased in patients with polyglandular failure as compared with a control population. Eleven of 42 relatives had a polyglandular failure illness. Disease prevalence correlated with HLA inheritance in some families, but not all. Patients and diseased relatives had a high incidence of immunologic dysfunction: autoantibodies, including antinuclear antibodies; elevated serum immunoglobulins (three of 16); abnormal skin tests (four of nine). Polyglandular failure appears to be an HLA-B8-associated syndrome with a high prevalence of disease in relatives. Immunologic dysfunction resulting from a gene(s) on chromosome 6, in linkage dysequilibrium with the HLA-B8 allele, may be a factor in the pathogenesis of polyglandular failure illnesses.
Significance of Urinary Gamma Globulin in Lupus Nephritis
Authors: Mary Betty Stevens, Barbara Knowles
Journal: New England Journal of Medicine (1962)

LABORATORY methods for the detection of early renal involvement in patients with systemic lupus erythematosus are not satisfactory. Pathologic changes of early lupus nephritis have been found in kidney biopsies from patients who have a normal urinary sediment, even when an Addis count is performed. Moreover, proteinuria may be so minimal initially that it escapes detection by routine testing of the random specimen.Two areas of investigation suggested the possibility that an increase in urinary gamma globulin can be anticipated in the early active stage of lupus nephritis. In the first place, there is evidence from light and electron microscopy . . .
World cancer rates set to double by 2020
Authors: L. Eaton
Journal: BMJ (2003)

Worldwide cancer rates are set to double by 2020, a report published this week by the World Health Organization says.

Currently 10 million new cancers are diagnosed each year worldwide, but unless there is an effective prevention campaign, the number will rise to 20 million in 17 years' time, says the report. If preventive measures were adopted, that figure could be reduced by a quarter, it states.

“Cancer is emerging as a major problem globally, both …
Ewan Murray Will
Authors: A. G. Finley
Journal: British Journal of Dermatology (2006)

Journal Article Ewan Murray Will Get access A. G. Finley A. G. Finley Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 84, Issue 6, 1 June 1971, Page 598, https://doi.org/10.1111/j.1365-2133.1971.tb02550.x Published: 01 June 1971
The Mayo Lung Cohort: A Regression Analysis Focusing on Lung Cancer Incidence and Mortality
Authors: Gary M. Strauss
Journal: Journal of Clinical Oncology (2002)

PURPOSE: The Mayo Lung Project has been interpreted as negative because it failed to demonstrate a significant mortality reduction among those randomized to chest x-ray and cytology. In contrast, survival suggests that screening is highly effective. This report was undertaken to analyze the trial as a closed cohort study, in an effort to identify predictors of lung cancer incidence and mortality, and to determine whether survival or mortality was unbiased. PATIENTS AND METHODS: The Mayo Lung Cohort comprised all 9,192 randomized individuals. Cox proportional hazards regression was used both to determine predictors of incidence and mortality in the population and to identify predictors of mortality among cases. Survival analyses using intent-to-treat principles and measuring survival from randomization were used to evaluate length bias and lead-time bias. Multivariate Cox regression was used to investigate the extent to which the data are consistent with overdiagnosis. RESULTS: Cox regression demonstrates that, in addition to age and smoking, randomization to screening predicted increased lung cancer incidence (hazard ratio, 1.30; 95% confidence interval [CI], 1.06 to 1.60). Predictors of mortality were similar, except randomization to screening was not significant (hazard ratio, 1.06; 95% CI, 0.83 to 1.37). Among cases, survival was significantly superior in the experimental population. Higher incidence in the experimental group accounts for the mortality/survival discrepancy. Both lead-time and length biases can be excluded, because survival from randomization was superior in the experimental population. Overdiagnosis is eliminated because resection was the only significant multivariate predictor of survival. Overall, 50% of resected and 0% of unresected cases were cured. CONCLUSION: Survival was superior in the screened population, and this advantage was not attributable to lead-time bias, length bias, or overdiagnosis bias. Mortality was biased, because incidence differences confounded the ability of mortality to reflect the true effect of screening. Indeed, survival provided an unbiased surrogate for cure in the Mayo Lung Cohort.
Seasonal variations in levels of DNA adducts and X-spots in human populations living in different parts of Poland.
Authors: E Grzybowska, K Hemminki, M Choraźy
Journal: Environmental Health Perspectives (1993)

White blood cell DNA adducts were measured in coke oven workers, in residents from the area next to the coke oven in Silesia, Poland (highly industrialized region), and in residents from the rural area of Poland using the 32P-postlabeling technique. This method detected aromatic adducts including adducts formed by polycyclic aromatic hydrocarbons (PAHs). Highest levels of adducts in DNA were seen in the group of coke battery workers (6.9 adducts/10(8) nucleotides). Seasonal variations in levels of DNA adducts were observed both in residents of the district near the coke oven area and individuals from the rural area of Poland. Blood samples collected from people living near the coke oven in winter showed much higher levels of DNA adducts than blood samples obtained in summer (5.0 adducts/10(8) nucleotides in winter and 1.4 adducts/10(8) nucleotides in summer). The difference in the level of DNA adducts between winter and summer was smaller in the group of people living in the rural area (3.2 adducts/10(8) and 2.2 adducts/10(8), respectively). In most cases the levels of X-spots correlated with the levels of other DNA adducts. Correlation coefficients(r) between the levels of X-spots and other adducts ranged between 0.46 and 0.74 (p < 0.05), except for coke oven workers where no correlation was observed.
Reduced Fear of Hypoglycemia in Successful Islet Transplantation
Authors: Jeffrey A. Johnson, Maria Kotovych, Edmond A. Ryan, A.M. James Shapiro
Journal: Diabetes Care (2004)

The recent dramatic improvement in clinical outcomes in islet transplantation in type 1 diabetes with the Edmonton Protocol has led to considerable excitement in the field of diabetes (1,2). The unprecedented 1-year success rates provide considerable evidence of the clinical effectiveness of the procedure (2,3). However, the benefits of freeing or reducing insulin requirements for these patients must be weighed against the risks of the procedure itself, as well as the life-long immunosuppression. Before making this treatment available to a larger number of people with type 1 diabetes, measures of quality of care and of clinical effectiveness must be incorporated to fully evaluate the benefit of this treatment.

Episodes of severe hypoglycemia, a common occurrence in patients with labile type 1 diabetes and hypoglycemia unawareness, result in considerable fear and anxiety (4 …